Methods
The study population consisted of all comers who were treated exclusively with either SES or PES. Comparison was made between those receiving SES ( n =2459) vs. PES ( n =1139) at 3 years’ post-stent implantation. The primary end point was major adverse cardiac events (MACE) which included death, Q-wave myocardial infarction (QWMI), target vessel revascularization (TVR), and cumulative incidence of stent thrombosis (ST).
Methods
The study population consisted of all comers who were treated exclusively with either SES or PES. Comparison was made between those receiving SES ( n =2459) vs. PES ( n =1139) at 3 years’ post-stent implantation. The primary end point was major adverse cardiac events (MACE) which included death, Q-wave myocardial infarction (QWMI), target vessel revascularization (TVR), and cumulative incidence of stent thrombosis (ST).
Results
There was no difference between the SES and PES for the overall MACE rates at 3 years. There was no difference in TVR (SES=22.9%, PES=19.9%; P =.06), but there was a difference in unadjusted rates of death (SES=15.7%, PES=19.0%; P =.02) and QWMI (SES=0.8%, PES=2.1%; P =.003). After adjusting for baseline differences, including a composite analysis of death, QWMI, and ST, there was no significant difference in MACE or in any of its comprising end points ( Table 1 ). The incidence of ST was higher in the SES group (SES=2.2%, PES=1.6%; P =.22).
